Efficacy and safety of ceftazidime and avibactam sodium in the treatment of carbapenem-resistant organism infection

MAO Jiaojiao; CAO Guowen; ZHU Zhu; TAO Hong; XU Feng

doi:10.6039/j.issn.1001-0408.2023.16.12

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of ceftazidime and avibactam sodium in the treatment of carbapenem-resistant organism infection

更新时间：2023-08-24

- Efficacy and safety of ceftazidime and avibactam sodium in the treatment of carbapenem-resistant organism infection
- ZHONGGUO YAOFANG Vol. 34, Issue 16, Pages: 1984-1988(2023)
- 作者机构：
  
  苏州大学附属第二医院药学部，江苏苏州　215004
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.16.12
  CLC： R978.1+1
- Published：30 August 2023，
  
  Received：01 December 2022，
  
  Revised：10 July 2023，
扫描看全文
毛娇娇,曹国文,朱珠等.头孢他啶阿维巴坦钠治疗碳青霉烯类耐药革兰氏阴性菌感染的疗效与安全性 ^Δ[J].中国药房,2023,34(16):1984-1988.

MAO Jiaojiao,CAO Guowen,ZHU Zhu,et al.Efficacy and safety of ceftazidime and avibactam sodium in the treatment of carbapenem-resistant organism infection[J].ZHONGGUO YAOFANG,2023,34(16):1984-1988.
毛娇娇,曹国文,朱珠等.头孢他啶阿维巴坦钠治疗碳青霉烯类耐药革兰氏阴性菌感染的疗效与安全性 ^Δ[J].中国药房,2023,34(16):1984-1988. DOI： 10.6039/j.issn.1001-0408.2023.16.12.

MAO Jiaojiao,CAO Guowen,ZHU Zhu,et al.Efficacy and safety of ceftazidime and avibactam sodium in the treatment of carbapenem-resistant organism infection[J].ZHONGGUO YAOFANG,2023,34(16):1984-1988. DOI： 10.6039/j.issn.1001-0408.2023.16.12.

摘要

目的

观察头孢他啶阿维巴坦钠（CAZ/AVI）治疗碳青霉烯类耐药革兰氏阴性菌（CRO）感染的疗效和安全性。

方法

回顾性收集2019年9月－2022年3月在苏州大学附属第二医院住院治疗的CRO感染患者的资料，根据治疗方案的不同分为对照组（48例）和观察组（48例）。对照组患者静脉滴注注射用硫酸多黏菌素B 50万单位，q12 h，其中肾功能不全或接受肾脏代替治疗（CRRT）者不进行剂量调整；观察组患者以微量泵持续静脉泵入注射用CAZ/AVI 2.5 g，q8 h，持续2 h，其中肾功能不全者根据肌酐清除率调整剂量，接受CRRT者不进行剂量调整。比较两组患者的临床疗效、微生物学疗效和治疗前后的体温、白细胞（WBC）、C反应蛋白（CRP）、降钙素原（PCT），记录其预后情况和不良反应发生情况；通过Logistic回归分析筛选影响疗效的因素。

结果

观察组患者的有效率、微生物清除率均显著高于对照组（

＜0.05）。治疗后，两组患者的体温、PCT、CRP均显著低于同组治疗前，且观察组CRP显著低于同期对照组（

＜0.05）；两组的康复出院、转普通病房、死亡患者比例及总不良反应发生率比较，差异均无统计学意义（

＞0.05）。使用CAZ/AVI、延长用药疗程可能实现临床获益（比值比分别为1.146、7.707，

＜0.05），肺部感染、接受CRRT可能是导致治疗失败的独立危险因素（比值比分别为0.182、0.236，

＜0.05）。

结论

CAZ/AVI治疗CRO感染的疗效和安全性均较好，适当延长用药疗程可能会获得更高的有效率，而肺部感染或接受CRRT可能会导致治疗失败。

Abstract

OBJECTIVE

To observe the efficacy and safety of ceftazidime and avibactam sodium （CAZ/AVI） in the treatment of carbapenem-resistant organism （CRO） infection.

METHODS

The information of patients with CRO infection admitted to the Second Affiliated Hospital of Soochow University from September 2019 to March 2022 was collected， and the patients were retrospectively divided into observation group （48 cases） and control group （48 cases） according to the treatment plan. The control group was given Polycolistin B sulfate for injection intravenously at a dose of 500 000 U every 12 hours； no dose adjustment was performed in patients with renal insufficiency or receiving continuous renal replacement therapy （CRRT）. The observation group was given continuous micropump of CAZ/AVI for injection intravenously at a dose of 2.5 g every 8 hours for 2 continous hours； among them， the patients with renal insufficiency received an adjusted dose based on creatinine clearance， and no dose adjustment was performed in patients receiving CRRT. The clinical efficacy and microbiological efficacy as well as body temperature， white blood cell （WBC）， C-reactive protein （CRP） and procalcitonin （PCT） before and after treatment were compared between 2 groups. The prognosis and the occurrence of adverse drug reactions were recorded. The factors influencing the clinical efficacy were screened by Logistic regression analysis.

RESULTS

The effective rate and microbial clearance rate of the observation group were significantly higher than the control group （

＜0.05）. After treatment， body temperature， PCT and CRP of 2 groups were significantly lower than before treatment， and CRP of the observation group was significantly lower than the control group （

＜0.05）. There was no statistically significant difference between the two groups in terms of rehabilitation discharge rate， the proportion of patients transferred to general wards， the proportion of dead patients， and the total incidence of adverse drug reactions （

＞0.05）. CAZ/AVI and prolonging therapy duration were more likely to achieve clinical benefits （odds ratios of 1.146， 7.707，

＜0.05）， while lung infection and CRRT may be independent risk factors for treatment failure （odds ratios of 0.182， 0.236，

＜0.05）.

CONCLUSIONS

CAZ/AVI has good efficacy and safety in the treatment of CRO infection， the appropriate extension of antibacterial treatment time can achieve a higher clinical response rate， while lung infection or CRRT may lead to treatment failure.

关键词

头孢他啶阿维巴坦钠碳青霉烯类耐药革兰阴性菌感染疗效安全性

Keywords

carbapenem-resistant organisminfectionefficacysafety

references

王明贵. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制：中国专家共识[J]. 中国感染与化疗杂志，2017，17（1）：82-92.

TZOUVELEKIS L S，MARKOGIANNAKIS A，PSICHOGIOU M，et al. Carbapenemases in Klebsiella pneumoniae and other enterobacteriaceae：an evolving crisis of global dimensions[J]. Clin Microbiol Rev，2012，25（4）：682-707.

ESCANDÓN-VARGAS K，REYES S，GUTIÉRREZ S，et al. The epidemiology of carbapenemases in Latin America and the Caribbean[J]. Expert Rev Anti Infect Ther，2017，15（3）：277-297.

KOHLER P P，VOLLING C，GREEN K，et al. Carba-penem resistance，initial antibiotic therapy，and mortality in Klebsiella pneumoniae bacteremia：a systematic review and meta-analysis[J]. Infect Control Hosp Epidemiol，2017，38（11）：1319-1328.

杨帆，王明华. 值得期待的新β内酰胺酶抑制剂阿维巴坦及其复合制剂[J]. 第三军医大学学报，2013，35（23）：2498-2501.

《抗菌药物临床试验技术指导原则》写作组.抗菌药物临床试验技术指导原则[J].中国临床药理学杂志，2014，30（9）：844-856.

Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States[EB/OL].[2023-01-06].https//www.cdc.gov/drugresistance/pdf/threats-report/2019- ar-threats-report-508.pdfhttps://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.

中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识编写组，中国医药教育协会感染疾病专业委员会，中华医学会细菌感染与耐药防控专业委员会. 中国碳青霉烯耐药肠杆菌科细菌感染诊治与防控专家共识[J]. 中华医学杂志，2021，101（36）：2850-2860.

CHINET数据云.肺炎克雷伯菌对亚胺培南和美罗培南耐药变迁[EB/OL].[2023-06-26].http：//www.chinets.com/data/germyearhttp://www.chinets.com/data/germyear.

ZHONG H，ZHAO X Y，ZHANG Z L，et al. Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of gram-negative bacterial infections：a syste-matic review and meta-analysis[J]. Int J Antimicrob Agents，2018，52（4）：443-450.

SHIELDS R K，POTOSKI B A，HAIDAR G，et al. Clinical outcomes，drug toxicity，and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections[J]. Clin Infect Dis，2016，63（12）：1615-1618.

VAN DUIN D，LOK J J，EARLEY M，et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae[J]. Clin Infect Dis，2018，66（2）：163-171.

NICOLAU D P，SIEW L，ARMSTRONG J，et al. Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens[J]. J Antimicrob Chemother，2015，70（10）：2862-2869.

CHEAH S E，WANG J P，NGUYEN V T，et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models：smaller response in lung infection[J]. J Antimicrob Chemother，2015，70（12）：3291-3297.

ZHOU C E，JIN L Y，WANG Q，et al. Bloodstream infections caused by carbapenem-resistant enterobacterales：risk factors for mortality，antimicrobial therapy and treatment outcomes from a prospective multicenter study[J]. Infect Drug Resist，2021，14：731-742.

DAIKOS G L，TSAOUSI S，TZOUVELEKIS L S，et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections：lowering mortality by antibiotic combination schemes and the role of carbapenems[J]. Antimicrob Agents Chemother，2014，58（4）：2322-2328.

中国医药教育协会感染疾病专业委员会，中华医学会呼吸病学分会，中华医学会重症医学分会，等. 中国多黏菌素类抗菌药物临床合理应用多学科专家共识[J]. 中华结核和呼吸杂志，2021，44（4）：292-310.

GUTIÉRREZ-GUTIÉRREZ B，SALAMANCA E，DE CUETO M，et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing enterobacteriaceae（INCREMENT）：a retrospective cohort study[J]. Lancet Infect Dis，2017，17（7）：726-734.

陈昆，王玥媛，刘梦颖，等. 1例头孢他啶/阿维巴坦个体化给药案例报道[J]. 上海医药，2021，42（1）：74-77.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of tofacitinib combined with hydroxychloroquine in the treatment of refractory rheumatoid arthritis

Meta-analysis of efficacy and safety of sedative therapy with midazolam and dexmedetomidine/propofol in critically ill patients undergoing mechanical ventilation

Efficacy and safety of tyrosine kinase inhibitors in the treatment of HER2-positive breast cancer： a meta-analysis

Efficacy and safety of domestic Paliperidone extended-release tablets in the treatment of stable schizophrenia

Clinical observation of herombopag combined with recombinant human thrombopoietin in the treatment of primary immune thrombocytopenia

Related Author

WANG Mingjie

XU Fengjin

ZHANG Yan

XUE Yan

WU Jiaqian

SU Dan

SHAO Tenghao

YU Zhanbiao

Related Institution

Dept. of General Medicine， Hengshui Municipal People’s Hospital

College of Clinical Medicine， Hebei Medical University

Dept. of Rheumatology and Immunology， Hengshui Municipal People’s Hospital

Dept. of Intensive Care Medicine， the Fourth Hospital of Hebei Medical University

Dept. of Intensive Care Medicine， the Affiliated Hospital of Hebei University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰